Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59


Successful treatment of primary refractory anemia with a combination regimen of all-trans retinoic acid, calcitriol, and androgen.

Zhang W, Zhou F, Cao X, Cheng Y, He A, Liu J, Ma X, Chen G.

Leuk Res. 2006 Aug;30(8):935-42. Epub 2006 Jan 30.


[Retrospective observation of curative effects on MDS refractory anemia with combination of all-trans retinoic acid, 1, 25-dihydroxyvitamin D3 and androgen].

Zhou FL, Zhang WG, Cao XM, Chen YX, He AL, Liu J, Zhao WH, Ma XR, Chen G.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2005 Oct;13(5):861-6. Chinese.


[Long-term effects of androgen combined with low dose all-trans-retinoic acid on myelodysplastic syndrome: follow-up of 60 cases].

Guan M, Chen SC, Ge CW.

Zhonghua Yi Xue Za Zhi. 2009 Apr 7;89(13):919-22. Chinese.


Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.

Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, Romanski A, Kramer OH, Kampfmann M, Hoelzer D, Neubauer A, Ruthardt M, Ottmann OG.

Cancer. 2005 Dec 15;104(12):2717-25.


High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma.

Morris MJ, Smaletz O, Solit D, Kelly WK, Slovin S, Flombaum C, Curley T, Delacruz A, Schwartz L, Fleisher M, Zhu A, Diani M, Fallon M, Scher HI.

Cancer. 2004 May 1;100(9):1868-75.


[Low dose all-trans retinoic acid and androgen therapy for patients with myelodysplastic syndrome].

Guan M, Chen SC, Li RS, Ge CW, Zhu HL.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2004 Dec;12(6):774-8. Chinese.


Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.

Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM, Garcia-Manero G.

Blood. 2007 Oct 1;110(7):2302-8. Epub 2007 Jun 27.


A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.

Khan KD, Emmanouilides C, Benson DM Jr, Hurst D, Garcia P, Michelson G, Milan S, Ferketich AK, Piro L, Leonard JP, Porcu P, Eisenbeis CF, Banks AL, Chen L, Byrd JC, Caligiuri MA.

Clin Cancer Res. 2006 Dec 1;12(23):7046-53.


High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.

Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, Lee CR, Taylor D, Zhang L, Man S, Baruchel S, Stempak D, Bertolini F, Crump M.

Clin Cancer Res. 2006 Sep 1;12(17):5190-8.


Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.

Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.

Clin Ther. 2008 Jun;30(6):1102-12. doi: 10.1016/j.clinthera.2008.06.013.


Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes.

Ferrero D, Darbesio A, Giai V, Genuardi M, Dellacasa CM, Sorasio R, Bertini M, Boccadoro M.

Br J Haematol. 2009 Feb;144(3):342-9. doi: 10.1111/j.1365-2141.2008.07465.x. Epub 2008 Nov 19.


Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.

Sacchi S, Pozzi S, Marcheselli R, Federico M, Tucci A, Merli F, Orsucci L, Liberati M, Vallisa D, Brugiatelli M; Italian Lymphoma Study Group..

Cancer. 2007 Jul 1;110(1):121-8.


Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.

Inada S, Tomidokoro T, Fukunari H, Sato T, Hatano T, Nishimura A, Kawauchi Y, Nikkuni K, Shimizu T, Sato T, Yanagi M, Takahashi S, Yoshida H, Sugita M, Hayashi T.

Cancer Chemother Pharmacol. 2009 Jan;63(2):267-73. doi: 10.1007/s00280-008-0736-4. Epub 2008 Apr 1.


[Multiple discriminant analysis for prognosis of refractory anemia].

Kobaba R, Kousaki M, Andou S, Okuda K, Tamura A, Miyazaki E, Inoue N, Okamoto T, Takemoto Y, Kanamaru A, et al.

Rinsho Ketsueki. 1991 Aug;32(8):815-21. Japanese.


Megakaryocytic growth in patients with refractory anemia is suppressed by treatment with interferon alpha.

Hofmann WK, Kalina U, Seipelt G, Hoffmann K, Wagner S, Hoelzer D, Ottmann OG.

Eur J Haematol. 1999 May;62(5):336-40.


[Prednisolone, 1 alpha hydroxyvitamin D3 and androgens in the management in patients with refractory anemias].

Yoshida Y, Yamagishi M.

Gan To Kagaku Ryoho. 1988 Apr;15(4 Pt 2-2):1178-82. Japanese.


Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients.

Dai CW, Zhang GS, Shen JK, Zheng WL, Pei MF, Xu YX, Cao YX, Yi Y, Yang JJ, Peng HL, Zhong HY, Li RJ.

Acta Haematol. 2009;121(1):1-8. doi: 10.1159/000204472. Epub 2009 Feb 26. Erratum in: Acta Haematol. 2009;121(4):243.


All-trans retinoic acid in association with low dose cytosine arabinoside in the treatment of acute myeoid leukemia in elderly patients.

Di Febo A, Laurenti L, Falcucci P, Tosti ME, Fianchi L, Pagano L, Leone G.

Am J Ther. 2007 Jul-Aug;14(4):351-5.


Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.

Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, O'Brien S, Andreeff M, Giles FJ.

Clin Cancer Res. 2006 Sep 1;12(17):5165-73.

Supplemental Content

Support Center